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The aim of this study was to investigate the long-term effectiveness and safety of inhaled antibiotic treatment in 
non-cystic fibrosis patients with bronchiectasis and chronic infection by Pseudomonas aeruginosa, after standard 
endovenous and oral therapy for long-term control of the infection had failed. After completing a 2-week 
endovenous antibiotic treatment to stabilize respiratory status, 17 patients were randomly allocated to a 12-month 
treatment either with inhaled ceftazidime and tobramycin (group A) or a symptomatic treatment (group B). One 
patient from group A abandoned inhaled treatment because of bronchospasm and another from group B died before 
the end of the study. The remaining 15 patients, seven from group A and eight from group B, completed the study. 
Both groups had similar previous characteristics. The number of admissions and days of admission (mean 5 SEM) of 
group A [0,6 (1.5) and 13.1 (34.8)] were lower than those of group B [2,5 (2.1) and 57.9 (41.8)] (P<O+l5). Forced vital 
capacity (FVC), forced expiratory volume in 1 set (FEV,)> PAO, and PAGO, were similar in the two groups at the 
end of follow-up, showing a comparable decline in these parameters. There were no significant differences either in 
the use of oral antibiotics or in the frequency of emergence of antibiotic-resistant bacteria between groups. 
Microbiological studies suggested that several patients had different Pseudomonas aerugihosn strains. None of the 
patients presented impaired renal or auditory function at the end of the study. This study suggests that long-term 
inhaled antibiotic therapy may be safe and lessen disease severity in non-cystic fibrosis patients with bronchiectasis 
and chronic bronchial infection by Pseudomonas aeruginosa which do not respond satisfactorily to antibiotics 
administered via other routes. 
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Introduction 
In patients with cystic fibrosis (CF), Pseudomonas aerugi- 
nosa (PA) bronchial infection, once established, is rarely 
eliminated, leading to chronic bronchial infection by PA 
(CBIPA), a well-known complication in these patients (1). 
The change of PA to the mucoid phenotype may be 
associated with deterioration in lung function and an 
increase in morbidity and mortality, even though the 
patient is receiving standard oral or endovenous treatment 
(2). 
Since the first study by Hodson (3); several peer-reviewed 
reports (4-13) have evaluated the efficacy of inhaled 
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antibiotic therapy in the evolution of patients with CF and 
CBIPA. A significant beneficial effect of inhaled antibiotic 
therapy, implying fewer hospital admissions owing to res- 
piratory exacerbation (4;8) and less respiratory function 
impairment, (3,7-g: 12,13) has been demonstrated. A recent 
study (14), in which a meta-analysis was applied to 
integrate the results of randomized controlled trials, 
really established that treatment may reduce pulmonary 
exacerbations and improve spirometric lung function. 
In patients with non-CF-based bronchiectasis, Nicotra 
et al. (15) showed PA to be cultured in almost 31% and the 
most frequent micro-organism in sputum. Wilson et al. (16) 
stated that all 22 non-CF bronchiectasic patients from 
whom a PA culture was obtained on an exacerbation-free 
day were chronically infected with the bacterium and had 
more hospital admissions and worse health-related quality 
of life than other bronchiectasic patients. Furthermore, 
CBIPA in non-CF patients with bronchiectasis has been 
associated with extensive lung disease and severe lung 
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obstruction (16,17) and, recently, a rapid decline in lung 
function (18). Thus, CBIPA in this population could be 
more frequent and significant than generally supposed. It 
has been suggested (19) that long-term nebulised antibiotics 
should be considered in these patients when antibiotics by 
other routes would have been unsuccessful. However, there 
are no clinical trial data to support the benefits of this 
therapy (20). 
The purpose of our study was to ascertain the long- 
term efficacy of home-inhaled antibiotic therapy in the 
outcome of non-CF patients with bronchiectasis and 
CBIPA who fail to respond satisfactorily to antibiotics by 
other routes. 
Material and Methods 
PATIENTS 
Between 1993 and 1994, 17 patients who met the conditions 
stated below were enrolled at two university centres. All 
patients had a diagnosis of bronchiectasis confirmed by 
bronchography, thoracic computed axial tomography, or 
both. Two sweat tests were normal in all cases. Blood 
samples were all negative for 31 CF mutations, including 
AF508, G542X and N1303K, the most frequent mutations 
in Spain (21). A study was carried out to ensure that 
immunodeficiency, enzymatic deficiency and congenital dis- 
ease were not the cause of the bronchiectasis. Four patients 
had had tuberculosis, and two whooping cough in infancy. 
Patients had been treated at our hospitals for almost 2 years 
before they entered the study owing to respiratory exacer- 
bations and because they had been difficult to control in the 
long term. PA had been grown consistently from the 
sputum. At least three positive cultures during the year 
prior to entering the study were obtained in each patient. 
No other pathogens were found in the sputum samples at 
the beginning of the trial. The patients had been treated at 
least once with ciprofloxacin p.o. (500 mg every 12 h for 3 
weeks) in the last 3 months because of exacerbation without 
recovery or with relapse of symptoms. Patients with 
p-lactam or aminoglycoside hypersensitivity or bacterial 
resistance in the antibiogram and those with kidney failure 
were excluded from the study. 
The study was approved by the ethics committee of each 
centre. All patients provided informed consent. 
STUDY 
This was a pilot, prospective, randomized, non-blinded 
trial. Patients were admitted owing to failure to recover 
from respiratory exacerbation or relapse of symptoms. 
Appropriate symptomatic treatment was then adminis- 
tered, including oxygen, bronchodilators and corticoster- 
oids. All patients completed a routine 2-week endovenous 
antibiotic treatment (ceftazidime 100 mg kg - ’ day- ‘; 
tobramycin 4 mg kg- 1 day - ‘) following the standard pro- 
tocol of our hospitals until their respiratory status was 
stabilized. Patients were then randomly allocated to a 
12-month treatment either with the same two antibiotics by 
inhalation route (ceftazidime 1000 mg 12 h- ‘; tobramycin 
100 mg 12 h- ‘) in group A or a symptomatic treatment in 
group B. All nebulised antibiotics were diluted in physi- 
ological saline to form a solution of approximately 8 ml. 
The solutions were administered separately twice a day 
using a jet nebuliser (System 22 Acorn, Medic-Aid, U.K.) 
driven by high flow-rate compressor (CR60, Medic-Aid, 
U.K.). This combination has proved useful for the nebuli- 
sation of antibiotics (22). Recent requirements established 
by the British Thoracic Society were also fulfilled (20). 
Patients attended the outpatient clinic at the start of the 
study, during weeks 2,4 and 8 and later during months 4,6, 
9 and 12. At each visit clinical history was recorded, 
patients were physically examined and asked about their 
treatment compliance and adverse effects. Chest X-ray, 
blood analysis, spirometry, arterial gasometry and sputum 
cultures were performed at months 1,6 and 12. Audiometry 
was performed at the end of the study. 
Supplementary use of oral antibiotics was permitted if a 
patient had an exacerbation, defined as more frequent 
coughing, more dyspnoea and an increase in sputum vol- 
ume and purulence (23). The decision on hospital admission 
was taken by an A&E physician who was unaware of the 
study. Patients were treated in each new admission with the 
same antibiotic regimen used in the first. In accordance with 
the standard protocol of our hospitals, the endovenous 
antibiotic treatment was only changed if there was also 
clinical impairment in addition to bacterial resistance 
demonstrated by the antibiogram. Ceftazidime was 
replaced by piperacillin (200 mg kg - ’ day- ‘) and 
tobramycin by amikacine (15 mg kg- ’ day- ‘). The deci- 
sion on hospital discharge was also taken by a physician 
who was unaware of the study. If an endovenous antibiotic 
had been changed on admission, antibiotic inhaled at 
home was also changed. Ceftazidime was replaced by 
piperacillin (100 mg 12 h - ‘) and tobramycin by amikacine 
(100 mg 12 h- ‘). 
Microbiological study of sputum was performed if the 
latter fulfilled determined quality criteria on microscopic 
examination (24). The study included: Gram smear, con- 
ventional culture by standard microbiological loop in blood 
agar and McConkey media and quantitative culture by 
0.001 ml calibrated loop with a previous dilution in 
1 ml of sterile distilled water in chocolate agar. The 
threshold for detecting bacteria was lo6 colony-forming 
units (cfu ml-‘) in chocolate agar, but was lower in 
blood agar and McConkey media. PA was identified by 
conventional microbiology methods and the AMS Vitek 
(Bio Merieux, Marey-Etoile, France) system. The anti- 
biogram was carried out with an automated system Aladin 
(Ditasa, New York, U.S.A.) of microdilution in broth. The 
PA strains of 13 patients of one of the hospitals were 
serotyped and phagotyped in the National Microbiology 
Laboratory of Majadahonda (Madrid) [serotype by the 
IATS rules (25) and phagotype by the set CPHL (26)]. 
End-points studied were the number of hospital admis- 
sions, the number of hospitalization days, oral antibiotic 
use, forced vital capacity (FVC), forced expiratory volume 
in 1 set (FEV,), PAO,, PACO,, drug toxicity and the 
emergence of bacterial resistance. 
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TABLE 1. Characteristics of the study population (group A: inhaled; group B: non-inhaled) at 
enrolment 
Group A Group B 
(n=7) (n=S) P-value 
Men/women 
Age (years)* 
Bronchiectasic lobes* 
Previous PA infection (days)*? 
Admissions 2 years prior to study* 
Admissions 1 year prior to study* 
Last sputum (cfn ml- ‘)*$ 
FVC (ml - ‘)* 
FEV, (ml - ‘)* 
FEV, (% pred.)” 
PAO, (mmHg)* 
PACO, (mmHg)* 
6/l 414 ns. 
62.0 (8.5) 61.4 (10.3) ns. 
4.0 (1.5) 3.0 (1.3) ns. 
717.7 (606.7) 539.9 (446.8) ns. 
2.3 (0.9) 2.1 (1.1) n.s. 
2.1 (1.1) 2 (0.9) n.s. 
> lo7 (0) >107 (0) n.s. 
1850 (1016) 1696 (597) ns. 
1037 (386) 866 (225) n.s. 
62.3 (19.9) 56.2 (21.4) n.s. 
69.0 (8.2) 63.4 (12.6) n.s. 
41.3 (7.4) 42.5 (5.3) n.s. 
*Values are means & SEM. 
IPA: Pseudomonas aeruginosa. 
IExpressed in colony-forming units per ml of sputum. 
n.s., not significant. 
STATISTICAL ANALYSIS 
Comparability of the treatment groups was assessed by 
Fisher’s exact test in the case of proportions and 
the Mann-Whitney U- or Wilcoxon test in the case of 
continuous variables. 
Results 
Seventeen patients were initially included. One patient from 
group A, who had severe bronchial hyperactivity, aban- 
doned inhaled treatment because of bronchospasm, despite 
receiving intense bronchodilator treatment. Another patient 
from group B died from respiratory failure at 300 days of 
follow-up. The remaining 15 patients, seven from group A 
and eight from group B, completed the study. Both groups 
had similar previous characteristics (Table 1). When admis- 
sions 2 years and 1 year before the study were compared, 
the means were similar in the two groups. 
The number of admissions (mean + SEM) was lower 
(PcO.05) in group A IO.6 (1.5)] than in group B [2.5 (2,1)]. 
Also, the days of admission (mean i SEM) were lower 
(PcO.05) in group A [13.1 (34.8)] than in group B [57.9 
(41.8)] (Table 2). Only one patient from group A required 
admission, on four occasions. The remaining patients in 
this group were not admitted. In contrast, all patients 
except one from group B required admission. There was no 
significant difference in the use of oral antibiotics between 
groups. 
FVC, FEV,, PAO, and PACO, were similar in the two 
groups at the end of follow-up. Decline of these pulmonary 
function parameters was similar in both groups. Micro- 
scopic study of sputum samples in both patient groups 
revealed the presence of abundant Gram-negative bacilli 
accompanied, in most cases, by Gram-positive cocci, 
mainly streptococci. PA was cultured in all samples from 
all patients. During follow-up, and in addition to PA, in 
two patients (one from each group studied) Streptococcus 
pneumoniae were isolated in some samples in one and 
Haemophilus infl~enzae in the other. No other bacteria or 
yeasts were detected. Three patients, two of whom belonged 
to group A, presented transient negative PA in sputum 
culture for more than 3 months. However, in the last 
sputum culture performed all patients of both groups 
presented abundant PA colonies. One patient from group A 
who did not receive endovenous antibiotics presented resist- 
ance to tobramycin in the antibiogram, with no clinical 
worsening. PA remained sensitive to ceftazidime and 
tobramycin in the other patients of this group. Four 
patients from group B developed resistance to ceftazidime, 
although in two of them this was only observed on a single 
antibiogram. Resistance to tobramycin was observed at the 
same time in one of these four patients. In three of these 
patients, the bitherapy administered was modified since the 
change in sensitivity to the antibiotic was accompanied by 
clinical worsening. PA serotypes and phagotypes were 
investigated in 13 patients: 75.7% of strains were sero- 
typable, with serotypes 011 (53.8%), 010 and 015 (38.5%) 
and 01-03 (23.1%) predominating, and 64.3% of isolates 
were phagotypable. It was notable that all but five patients 
had different PA strains. None of the patients presented 
impaired renal or auditory function at the end of the study. 
Discussion 
In CF: the genetic defect favours bronchial wall injury and 
permits early CBIPA. Thus, nearly 98% of the CF population 
is colonized after lo-14 years (27). CBIPA in non-CF 
patients with bronchiectasis seems to occur in older patients, 
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TABLE 2. Summary of group changes (group A: inhaled; group B: non-inhaled) during follow-up 
Group A Group B 
(n=7) (n=8) P-value 
Number of admissions (mean)* 
Days of admission (mean)* 
Oral antibiotic use* 
FVC (ml- I)* 
FEV, (ml - ‘)* 
FEV, (% pred.)* 
PAO, (mmHg)* 
PACO, (mmHg)* 
A FVC (ml - ‘)*T 
A FEV, (ml- I)*? 
APAO, (mmHg)*t 
APACO, (mmHg)*f 
Emergence antibiotic-resistant bacteria 
0.6 (1.5) 2.5 (2.1) 0.023 
13.1 (34.8) 57.9 (41.8) 0.033 
1.1 (1.2) 4.0 (4.5) n.s. 
1655 (839) 1466 (355) n.s. 
932 (415) 803 (216) n.s. 
61.7 (23.1) 56.1 (16.0) ns. 
67.6 (9.7) 62.2 (15.6) n.s. 
43.4 (9.0) 43.5 (6.9) n.s. 
- 117.1 (314.4) - 229.2 (475.7) ns. 
- 104.3 (81.6) - 63.1(202.5) n.s. 
1.4 (4.4) - 1.1 (9.5) ns. 
1.1 (32) 0.9 (2.8) ns. 
l/7 418 n.s. 
“Values are means + SEM. 
tChange over time. 
ns., not significant. 
as in our series, when severe lung disease, a possible 
predisposing factor for CBIPA, has developed (16-18). 
The results of this study show that long-term inhaled 
antibiotic therapy influenced severity of the illness in non- 
CF patients with bronchiectasis and CBIPA. This therapy 
decreased the number of hospital admissions and admission 
days. These findings are consistent with previous reports in 
CF patients (4,8). The use of placebo was not considered for 
different reasons: firstly, because of the difficulty in ad- 
equately matching for all the distinctive characteristics of the 
inhaled antibiotics used in the study; secondly, it was consid- 
ered difficult to administer a placebo over such a long period 
of time; and finally, exactly how a nebulised placebo can 
influence long-term outcome remains unknown. In fact, it 
has been suggested (28) that a negative effect of the placebo 
on lung function in one of the best designed studies (13) 
cannot be ruled out. In the present study, both groups were 
controlled equally during follow-up, and the decision to 
admit and discharge patients was taken by physicians not 
participating in the study. Thus, it is unlikely that the lack of 
placebo may have influenced those end-points. Moreover, 
the fact that the number of admissions 2 years and 1 year 
before the study were similar supports our results. 
Several peer-reviewed reports in CF patients have found 
improvement in lung function after aerosolized antibiotics 
(3,7-9,12,13). Contrary to these studies, the inhaled anti- 
biotic therapy in our study was not associated with an 
improvement in lung function. However, only one of the 
positive studies mentioned had a duration longer than 
6 months (12), whereas our patients were treated for 
12 months. This longer study period could have had an 
influence, as a decline in the efficacy of inhaled antibiotic 
therapy in lung function when administered for more than 
28 days has been described (11,13). In fact, significant 
differences in lung function were not observed in three 
(4,5,10) out of four reports (4,5,10,12) of CF patients with 
a follow-up longer than 6 months. Moreover, our patients, 
whose progress may differ from CF, had severe irreversible 
lung disease and low function at enrolment which may have 
made it difficult to establish any improvement in lung 
function after inhaled therapy. 
Due to the rarity of this condition numbers of patients 
are low and therefore a cross-over design could have been 
a possible option. However, the present study lasted for 
12 months, during which time the characteristics of the 
patients may have changed, therefore this type of design 
could potentially have been flawed (29). 
Despite the severe chronic bronchial obstruction seen in 
our patients, long-term administration of inhaled anti- 
biotics appears to be safe. Bronchoconstriction excluded 
one patient from the study, but did not occur in any others. 
Although risk associated with tobramycin inhalations is 
possible, due to unpredictable systemic absorption, in our 
study patients’ renal and auditory measurements remained 
within the normal range. The resistance of PA to inhaled 
antibiotics has been a matter of controversy. Most reports 
on CF show no further emergence of antibiotic-resistant PA 
strains (3,5,7,13). However, inhaled therapy in these studies 
was only used for short periods of time. The effect of 
long-term administration is not well known. In our 12- 
month study, the frequency of emergence of PA-resistant 
organisms was no higher in patients with inhaled therapy 
than in the other group. Moreover, it was only necessary to 
change the endovenous antibiotics owing to bacterial resist- 
ance and poor clinical response in patients without inhaled 
antibiotics. This criterion was taken into account as current 
microbiological evidence separates the development of 
in vitro pseudomonal resistance from adverse clinical out- 
come in CF with CBIPA (14). The fact that several patients 
in our study had different PA strains might also have 
influenced our decision to change the antibiotics if there 
was clinical impairment. 
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We studied a group of difficult-to-control non-CF patients 
with severe lung disease secondary to bronchiectasis and 
CBIPA. Although this was an uncontrolled trial, our results 
suggest that these patients could benefit from long-term 
inhaled antibiotic therapy. However, the time scale and 
frequency of treatment as well as the type, dose and amount 
of antibiotics cannot be definitively recommended at this 
time. 
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